

ANCIENT MEDICAL TRADITIONS AND MODERN DEMENTIA CARE

An evidence-informed narrative review of historical leads, current treatments, and responsible research priorities

Document type	Evidence-informed narrative review and research concept paper
Prepared for	The MemoryHelm Project
Date	16 September 2026
Scope	Dementia treatment and risk reduction; traditional medical knowledge; ethical translation; assistive-technology research

Central conclusion

Traditional knowledge can reveal valuable hypotheses, molecules, practices, and models of care. It does not, by itself, establish that a therapy is safe or effective. The strongest path forward is respectful partnership, rigorous testing, transparent negative results, and human-centred support – not the assumption that a hidden ancient cure has already been found.

This paper is for research planning and education. It is not medical advice, a clinical guideline, or a substitute for diagnosis and care by qualified health professionals.

Abstract

Dementia is a syndrome caused by multiple diseases, not a single disorder with one universal mechanism. Despite important advances, no treatment currently cures dementia. Symptomatic medicines can help selected patients, and anti-amyloid monoclonal antibodies can modestly slow decline in some people with early Alzheimer's disease, but they require biomarker-confirmed diagnosis, careful selection, and safety monitoring. This narrative review asks a narrower and more productive question than whether an ancient cure has been overlooked: what can historical and traditional medical knowledge contribute to modern dementia research, and how should candidate ideas be evaluated? The review examines examples from European ethnobotany, Chinese medicine, Ayurvedic traditions, and Indigenous knowledge from the Americas, while avoiding the false assumption that distinct cultures form a single body of "ancient medicine." Galantamine illustrates successful translation from a plant-derived lead to a regulated symptomatic medicine. In contrast, large or well-controlled studies of Ginkgo biloba, curcumin, Bacopa monnieri, and huperzine A have yielded negative, inconsistent, or very low-certainty findings. Uncaria tomentosa (cat's claw) has preclinical signals but lacks adequate human evidence for dementia, and commercial conflicts in parts of that literature require particular caution. Indigenous scholarship contributes not only possible biological leads but also culturally safe models of care and principles of community authority, consent, reciprocity, and benefit-sharing. The paper proposes an evidence ladder and a responsible translation pipeline from community partnership and source authentication through standardization, toxicology, pharmacokinetics, phased trials, independent replication, and post-market monitoring. It also outlines a research agenda for MemoryHelm as a human-guided assistive system, not a treatment, including co-design, person-specific routines, caregiver approval, tiered safety, and outcomes centred on autonomy, task completion, adverse events, and caregiver burden.

Keywords: dementia; Alzheimer's disease; traditional medicine; ethnopharmacology; galantamine; huperzine A; Indigenous data governance; assistive technology; human-in-the-loop AI; MemoryHelm

Key findings

- There is no credible evidence that an ancient or hidden cure for dementia has already been discovered. Absence of proof is not proof of absence, but a therapeutic claim must survive modern testing before it can guide care.
- Traditional knowledge is scientifically valuable as a source of hypotheses. Galantamine shows that a natural-product lead can become an evidence-based medicine, although it remains symptomatic rather than curative.
- Historical descriptions of forgetfulness cannot be mapped directly onto modern Alzheimer's disease. Delirium, depression, vascular disease, sensory loss, normal ageing, and many neurological disorders can produce superficially similar descriptions.
- Negative and uncertain trials are informative. Ginkgo did not prevent dementia in a large randomized trial; curcumin, Bacopa, and huperzine A have not produced convincing clinical evidence sufficient for routine dementia treatment.
- Indigenous knowledge must be approached through community authority, culturally safe methods, reciprocity, and benefit-sharing – not as a catalogue of remedies available for extraction.
- MemoryHelm should be evaluated as assistive care technology. It must not be described as treating, preventing, or curing dementia unless future clinical evidence supports a regulated claim.

1. Introduction

Dementia affects memory, thinking, behaviour, communication, and the ability to perform everyday activities. The World Health Organization (WHO) estimated that 57 million people were living with dementia in 2021, with nearly 10 million new cases each year and more than 60% of affected people living in low- and middle-income countries. Alzheimer's disease is estimated to account for 60-70% of cases, but vascular, Lewy body, frontotemporal, mixed, infectious, metabolic, traumatic, and other causes make dementia biologically heterogeneous.[1]

The scale of this burden understandably creates urgency and hope. Historical medical systems contain centuries of observation about ageing, memory, behaviour, sleep, plants, diet, social roles, and caregiving. Some modern medicines have indeed emerged from natural products or traditional use. However, the statement "ancient people observed something useful" and the statement "a safe, effective treatment for a modern diagnosis exists" are separated by several demanding steps: accurate identification, reproducible composition, plausible exposure,

toxicology, controlled trials, clinically meaningful outcomes, independent replication, and ongoing safety surveillance.

A scientifically defensible hypothesis is therefore not that an ancient cure is waiting to be rediscovered, but that long-observed plants, practices, and care systems may contain testable leads. This distinction preserves curiosity while protecting people living with dementia from false hope, avoidable toxicity, drug interactions, financial exploitation, and delay of effective care.

2. Scope and method

This is an evidence-informed narrative review, not a systematic review or meta-analysis. It combines current public-health and clinical guidance with landmark randomized trials, systematic reviews, historical surveys, and selected studies of traditional or plant-derived candidates. The examples were chosen to test different parts of the claim that traditional knowledge might inform dementia treatment: successful translation (galantamine), mixed or weak clinical evidence (huperzine A and Bacopa), large negative evidence (Ginkgo), formulation and bioavailability challenges (curcumin), preclinical evidence with governance and conflict-of-interest concerns (cat's claw), and culturally safe care and research governance (Indigenous scholarship).

Evidence was interpreted using five questions: (1) Was the population clinically characterized? (2) Was the intervention standardized and its dose known? (3) Was there a credible comparator and adequate blinding? (4) Were outcomes clinically meaningful and measured long enough? (5) Were findings replicated independently, with harms and competing interests reported? Because this paper does not document a reproducible database search and screening process, it must not be presented as exhaustive.

3. Why historical “memory loss” is not automatically modern dementia

Retrospective diagnosis is intrinsically uncertain. Historical texts may describe forgetfulness, confusion, wandering, reduced judgement, behavioural change, frailty, or altered consciousness without the longitudinal history, neurological examination, laboratory tests, imaging, biomarkers, or neuropathology used today. A single description could refer to chronic neurodegeneration, delirium from infection, depression, stroke, medication effects, intoxication, sensory impairment, sleep disturbance, malnutrition, or normal ageing.

Translation adds another layer of uncertainty. Classical Chinese concepts, Ayurvedic categories, and the many distinct knowledge systems of Indigenous peoples cannot be assumed to correspond one-to-one with contemporary disease labels. Historical surveys can identify patterns and candidate interventions, but modern diagnostic criteria must be applied prospectively. This is not a dismissal of traditional observation; it is a safeguard against claiming specificity that the source material cannot support.[10]

4. The current clinical baseline

4.1 Treatment and support

No current treatment cures dementia.[1,2] Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, as well as the NMDA-receptor antagonist memantine, can provide symptomatic benefit for selected patients. Lecanemab and donanemab are disease-modifying anti-amyloid antibodies approved in the United States for appropriately selected people with early symptomatic Alzheimer's disease and confirmed amyloid pathology. In phase 3 trials they slowed decline on cognitive-functional measures over approximately 18 months, but did not restore lost function or stop progression. Amyloid-related imaging abnormalities, infusion reactions, eligibility constraints, costs, and the need for MRI monitoring are clinically important.[2-4]

Good dementia care also includes diagnosis of reversible contributors, review of medicines, management of cardiovascular and sensory conditions, treatment of pain and mood disorders, meaningful activity, sleep and mobility support, environmental adaptation, advance care planning, and support for family and professional caregivers. The appropriate plan depends on dementia subtype, stage, comorbidities, preferences, living environment, and capacity – not on a diagnosis alone.

4.2 Risk reduction is not the same as treatment

Population research indicates that a substantial share of dementia risk is associated with potentially modifiable factors across the life course. The 2024 Lancet Commission estimated a theoretical population-attributable fraction of about 45% across 14 factors.[5] This estimate does not mean that 45% of individual cases can certainly be prevented, nor that lifestyle change reverses established dementia. It describes population-level potential under assumptions about causality, exposure, and overlap.

Multidomain interventions are promising but nuanced. The FINGER trial reported a modest cognitive benefit from a two-year programme combining diet, exercise, cognitive training, social activity, and vascular-risk monitoring in at-risk older adults.[6] In the ACHIEVE hearing trial, the primary analysis across the full cohort was null, while a prespecified higher-risk subgroup showed slower cognitive decline.[7] A three-year randomized MIND-diet trial found no significant between-group difference in cognition or MRI outcomes.[8] These results support careful risk management and individualized prevention, not claims that a single behaviour or supplement cures dementia.

4.3 Evidence ladder used in this review

Level	What it can establish	What it cannot establish
Regulatory-quality randomized evidence	Benefit–risk for a defined intervention, population, dose, comparator, and outcome.	A universal cure; effectiveness outside the studied population; long-term safety beyond available follow-up.
Replicated controlled human studies	A credible clinical signal and approximate effect under specified conditions.	Routine use if studies remain small, biased, inconsistent, or use surrogate outcomes only.
Observational or traditional-use evidence	A pattern worth investigating; cultural meaning; feasibility and acceptability.	Causality, standardized dose, efficacy, or freedom from confounding and expectancy effects.
Animal, cellular, or computational evidence	Mechanistic plausibility and candidate prioritization.	Clinical benefit or safety in people with dementia.
Anecdote or commercial claim	A question or personal experience.	Generalizable effectiveness, causality, or a reliable benefit–risk estimate.

5. What selected traditional knowledge has contributed

5.1 Galantamine: a successful translation, not a cure

Galantamine, an acetylcholinesterase inhibitor derived historically from plants in the Amaryllidaceae family, is the clearest example in this review of a natural-product lead becoming an evidence-based dementia medicine. Ethnopharmacological histories link snowdrop and related plants to traditional uses, although the precise chain from folk practice to modern development is more complex than popular accounts sometimes imply.[9] Galantamine is now used for symptomatic treatment of mild-to-moderate Alzheimer’s dementia. It does not halt the underlying disease and may cause gastrointestinal and cardiovascular adverse effects; prescribing requires clinical judgement.[2]

The lesson is methodological. Traditional observation helped direct attention toward a biologically active plant family. Success came through isolation of an active molecule, dose standardization, pharmacology, manufacturing controls, clinical trials, and regulation – not by treating the historical remedy itself as sufficient proof.

5.2 Chinese medicine and huperzine A

Chinese medical literature contains longstanding descriptions of forgetfulness and age-related cognitive change, as well as multi-herb formulas and materia medica used for related symptom patterns.[10] These records are valuable for hypothesis generation but should not be retrofitted into a single modern category of Alzheimer’s disease.

Huperzine A, an alkaloid isolated from *Huperzia serrata*, inhibits acetylcholinesterase and has attracted substantial interest. In a multicentre U.S. randomized trial, 200 µg twice daily did not meet the primary cognitive endpoint. An exploratory signal at a higher dose was not sufficient to establish routine efficacy.[11] A later meta-analysis suggested possible improvement on some measures, but most included studies had a high risk of bias and evidence for quality of life was absent.[12] The appropriate conclusion is “promising but unproven,” not “effective ancient treatment.” Product quality, dose, adverse effects, and interactions also matter.

5.3 Ginkgo biloba: why large negative trials matter

Ginkgo has a long history of medicinal use and became one of the most prominent supplements promoted for memory. The Ginkgo Evaluation of Memory study randomized 3,069 older adults to standardized Ginkgo extract or placebo. It found no reduction in the incidence of all-cause dementia or Alzheimer's disease.[13] This does not prove that every Ginkgo preparation has no biological activity. It does show that historical use, plausible mechanisms, and smaller positive reports cannot override a large, well-conducted negative prevention trial for the tested product and dose.

5.4 Ayurvedic leads: curcumin and Bacopa monnieri

Curcumin, a constituent of turmeric, has antioxidant and anti-inflammatory properties in experimental systems. A small 24-week randomized trial in Alzheimer's disease found neither clinical nor biomarker evidence of efficacy and highlighted low systemic exposure as a major limitation.[14] Novel formulations may change pharmacokinetics, but a new formulation is a new intervention and requires its own safety and efficacy evidence.

Bacopa monnieri is traditionally associated with cognition in Ayurvedic practice. A 2022 systematic review of randomized evidence in Alzheimer's disease or mild cognitive impairment found no clear advantage over placebo or donepezil and rated the certainty of evidence very low.[15] Studies in healthy adults or people with subjective memory complaints cannot be assumed to demonstrate treatment of dementia.

5.5 Indigenous peoples of the Americas: biological leads and cultural safety

There is no single "Native American medicine." Indigenous nations and communities across North, Central, and South America have distinct languages, histories, healing systems, plants, governance, and relationships to knowledge. Combining them into one category risks scientific error and cultural harm.

Uncaria tomentosa, commonly called cat's claw, is an Amazonian vine with a history of Indigenous use. Laboratory and transgenic-mouse work has reported effects on amyloid and tau-related outcomes, but these are preclinical findings and do not demonstrate prevention or treatment of dementia in humans.[16] The U.S. National Center for Complementary and Integrative Health states that there have been very few high-quality human trials and no conclusive evidence supporting cat's claw for any health purpose; it may also interact with medicines or affect bleeding and immune function.[17] The cited preclinical paper reports equity and employment interests involving a commercial company, which does not invalidate the experiments but raises the importance of independent replication.[16]

Indigenous scholarship also makes a contribution that cannot be reduced to pharmacology: dementia care becomes more acceptable and humane when it respects community understandings of ageing, family, spirit, language, land, and collective identity, and when Elders, healers, people living with dementia, and caregivers help govern the research.[18] The CARE Principles of Collective Benefit, Authority to Control, Responsibility, and Ethics provide a practical complement to conventional open-data principles.[19] Consent to discuss knowledge is not automatically consent to publish it, patent it, commercialize it, or place it in an AI training set.

5.6 Comparative evidence map

Candidate or contribution	Traditional or historical connection	Best human evidence	Responsible conclusion
Galantamine	Amaryllidaceae plants; European/Eurasian ethnobotanical history	Regulated symptomatic medicine for selected Alzheimer's patients	Validated translation; symptomatic, not curative
Huperzine A	Huperzia serrata in Chinese materia medica	Primary U.S. trial negative at prespecified dose; biased small trials create uncertainty	Research candidate; not established routine therapy
Ginkgo biloba	Longstanding East Asian medicinal use	Large randomized prevention trial found no reduction in dementia	Do not recommend as a proven prevention strategy
Curcumin	Turmeric in South Asian food and Ayurvedic traditions	Small Alzheimer's trial found no clinical or biomarker efficacy	Mechanistic interest; clinical efficacy unproven
Bacopa monnieri	Ayurvedic cognitive tonic	Very low-certainty evidence; no clear benefit in dementia/MCI review	Insufficient evidence for dementia treatment

Candidate or contribution	Traditional or historical connection	Best human evidence	Responsible conclusion
Cat's claw	Amazonian Indigenous medicinal use	No adequate dementia trials; laboratory and animal findings only	Preclinical hypothesis; human benefit and safety unknown
Culturally safe Indigenous care	Community-specific models of wellbeing and healing	Qualitative and policy literature supports co-designed, culturally safe care	Important care and governance contribution; not a drug claim

6. What ancient knowledge can—and cannot—tell us

6.1 Contributions worth pursuing

- Candidate selection: repeated use can prioritize plants, preparations, diets, sensory practices, or routines for investigation.
- Longitudinal observation: traditional healers and families may recognize symptom patterns, contextual triggers, tolerability problems, and caregiving practices missed by narrow laboratory models.
- Whole-person care: many traditions emphasize purpose, identity, relationships, music, movement, familiar environments, and social roles – domains central to living well with dementia.
- Chemical diversity: natural products contain structures that can inspire purified molecules, analogues, or entirely new mechanisms.
- Research questions: discrepancies between traditional experience and modern results can reveal problems of species identification, preparation, dose, timing, outcome selection, or disease heterogeneity.

6.2 Claims that the evidence does not support

- That a remedy is safe because it is natural, ancient, or widely used.
- That a historical description establishes a modern diagnosis.
- That antioxidant, anti-inflammatory, amyloid-binding, or neuroprotective activity in a test tube predicts meaningful benefit in people.
- That a single anecdote or uncontrolled case series proves causality.
- That failure of one preparation proves all related plants or practices are ineffective – or, conversely, that a new formulation can inherit evidence from an older one.
- That publicly discussed Indigenous knowledge is ownerless or available for unrestricted extraction and commercialization.

7. A responsible translation pipeline

The pathway below treats traditional knowledge as the beginning of research, not the end. Each stage has a stopping rule. A candidate that fails identity, contamination, exposure, toxicology, or clinical-effect thresholds should not progress merely because its story is compelling.

- 1 Community partnership and governance.** Agree authority, consent, cultural boundaries, ownership, benefit-sharing, publication rules, and withdrawal processes before collecting knowledge or samples.
- 2 Source authentication.** Verify species, plant part, harvest conditions, preparation, provenance, and historical context; deposit voucher specimens where appropriate.
- 3 Standardization and quality.** Define chemical fingerprint, potency, contaminants, adulterants, batch variability, stability, and manufacturing controls.
- 4 Mechanism and exposure.** Establish plausible targets, absorption, metabolism, brain exposure, dose-response, and interactions; avoid equating test-tube concentration with achievable human exposure.
- 5 Safety before efficacy claims.** Conduct toxicology, interaction assessment, and cautious early-phase human studies, with special attention to frailty, polypharmacy, bleeding, liver injury, and cardiovascular effects.
- 6 Clinical validation.** Use populations characterized using biomarkers and clinical assessments, prespecified outcomes, adequate power, blinding, appropriate comparators, meaningful follow-up, and full adverse-event reporting.

- 7 Independent replication.** Require confirmation by teams without financial or intellectual dependence on the original claim, including pragmatic and diverse-population studies.
- 8 Implementation and monitoring.** Evaluate accessibility, cultural fit, cost, real-world safety, caregiver burden, equity, and long-term outcomes; maintain transparent pharmacovigilance.

8. Implications for MemoryHelm

8.1 Position the system accurately

MemoryHelm should be positioned as a human-guided assistive system for structuring and delivering familiar daily routines – not as a medical device that diagnoses, treats, prevents, or cures dementia unless a future regulatory and clinical pathway supports such claims. Its central principle states, “The caregiver remains at the helm. AI provides support, but people retain control.” This principle is aligned with the need for human oversight, but it must be implemented through measurable safeguards rather than branding alone.

Research on assistive technology in dementia is encouraging but not uniformly positive. A large randomized trial of a broad assistive-technology package did not significantly increase time living independently at home.[20] Smaller studies of prompting tools and recent experiments comparing visual, verbal, and task-breakdown strategies suggest that person-specific prompting may support some everyday activities, but evidence remains early and context-dependent.[21,22] MemoryHelm therefore needs task-level evaluation rather than assuming that “more technology” produces better outcomes.

8.2 Proposed staged research programme

Stage	Design	Primary questions and outcomes	Progression rule
0. Co-design	Workshops and interviews with people living with cognitive impairment, caregivers, clinicians, occupational therapists, and cultural/community advisers	Comprehension; dignity; desired autonomy; unacceptable tasks; language and sensory needs; data expectations	Proceed only when safety boundaries and user priorities are documented
1. Simulation and usability	Synthetic profiles and supervised laboratory tasks; no unsupervised high-risk actions	Prompt comprehension; task decomposition; false alarms; blocked-risk accuracy; caregiver editing time; accessibility	Predefined error thresholds and no unresolved critical hazards
2. Feasibility pilot	Small prospective study of low-risk familiar routines with caregiver approval	Recruitment; adherence; task initiation/completion; corrections; near misses; distress; caregiver workload	Independent safety review and acceptable feasibility
3. Controlled evaluation	Randomized or crossover comparison with usual reminders	Functional task performance; autonomy; usability; quality of life; caregiver time/burden; adverse events	Clinically meaningful benefit with acceptable harms
4. Pragmatic deployment	Multiple services, homes, languages, and dementia stages; implementation study	Generalizability; equity; sustained use; escalation patterns; privacy; cost; unintended dependence	Transparent reporting and post-deployment monitoring

8.3 Minimum safety and ethics requirements

- Every routine should be authored or explicitly approved by an accountable human before activation; AI-generated text should remain a draft.
- Risk should be tiered: low-risk routines may be approved normally; moderate-risk routines should require contextual clarification and stronger caregiver review; prohibited categories should remain blocked with no override in the ordinary workflow.
- The system should not independently prescribe medication, provide a diagnosis, direct emergency-service decisions, authorize financial transactions, control dangerous appliances, manage locks, or instruct unsupervised departure from the property.
- Person-specific capability matters. A task such as taking out rubbish is neither universally safe nor universally forbidden. The system should present relevant contextual information, including orientation, mobility, supervision, doors, weather, traffic, and the return plan, to support human judgement.
- Consent and assent should be ongoing. Repeated refusal, distress, confusion, or task deterioration should trigger review rather than increasingly forceful prompting.
- Collect only the data needed for the stated purpose; separate research consent from service use; encrypt sensitive data; define retention and deletion; log human edits, approvals, warnings, and adverse events.
- Measure both benefit and burden. A higher task-completion rate is not a success if it increases distress, surveillance, caregiver work, or unsafe independence.

9. Limitations of this review

This narrative review is selective and English-language dominant. It may underrepresent non-indexed scholarship, oral knowledge, community-controlled records, negative studies, and regional variations in preparation and practice. Traditional interventions are difficult to compare when species, extraction, dose, formulation, co-interventions, diagnostic criteria, and outcome measures differ. Some literature is affected by small samples, short follow-up, inadequate blinding, selective reporting, weak comparators, or commercial conflicts. Conversely, conventional trials may miss outcomes that communities value, including identity, participation, reciprocity, and spiritual wellbeing. These limitations strengthen the case for partnership and better research; they do not justify bypassing evidentiary safeguards.

10. Conclusion

Ancient and traditional medical knowledge deserves neither romantic acceptance nor reflexive dismissal. Its most defensible scientific role is to generate prioritized, culturally grounded hypotheses and to broaden the meaning of good care. Galantamine demonstrates that a plant-derived lead can survive the full path to regulated medicine, while the mixed, negative, and preclinical evidence for huperzine A, Ginkgo, curcumin, Bacopa, and cat's claw demonstrates why that path is indispensable.

The search for better dementia care should therefore proceed on two connected tracks. The first is biomedical: identify and rigorously test molecules, combinations, mechanisms, and prevention strategies. The second is human: preserve autonomy, identity, relationships, cultural safety, and practical support while disease-modifying science advances. MemoryHelm belongs on the second track unless and until evidence supports a different claim. Its opportunity is not to promise a cure, but to test whether carefully designed, caregiver-approved visual and voice routines can help people perform meaningful daily activities more safely and with less burden. That is a substantial and ethically sound research goal.

Medical and research note

People should not start, stop, or replace prescribed treatment with a herb or supplement on the basis of this review. Products may vary in composition and can interact with anticoagulants, antiplatelet drugs, medicines affecting heart rate, sedatives, immune therapies, and other treatments. Suspected cognitive decline warrants clinical assessment because some contributors are treatable and dementia subtype affects care. Any study involving people with cognitive impairment requires appropriate ethics review, capacity assessment, consent or authorized consent where applicable, ongoing assent, privacy protections, and an adverse-event plan.

References

1. World Health Organization. Dementia. Fact sheet. Updated 3 July 2026. [WHO fact sheet](#)
2. National Institute on Aging. How is Alzheimer's disease treated? U.S. National Institutes of Health. [NIA treatment overview](#)
3. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388:9–21. doi:10.1056/NEJMoa2212948. [PubMed](#)
4. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. *JAMA*. 2023;330(6):512–527. doi:10.1001/jama.2023.13239. [PubMed](#)
5. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *Lancet*. 2024;404(10452):572–628. doi:10.1016/S0140-6736(24)01296-0. [DOI](#)
6. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015;385(9984):2255–2263. doi:10.1016/S0140-6736(15)60461-5. [PubMed](#)
7. Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. *Lancet*. 2023;402(10404):786–797. doi:10.1016/S0140-6736(23)01406-X. [PubMed](#)
8. Barnes LL, Dhana A, Liu X, et al. Trial of the MIND diet for prevention of cognitive decline in older persons. *N Engl J Med*. 2023;389:602–611. doi:10.1056/NEJMoa2302368. [PubMed](#)
9. Heinrich M, Teoh HL. Galanthamine from snowdrop—the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. *J Ethnopharmacol*. 2004;92(2–3):147–162. doi:10.1016/j.jep.2004.02.012. [PubMed](#)
10. Liu P, Kong M, Liu S, Chen G, Wang P. History and experience: a survey of traditional Chinese medicine treatment for Alzheimer's disease. *Evid Based Complement Alternat Med*. 2014;2014:642128. doi:10.1155/2014/642128. [DOI](#)
11. Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. *Neurology*. 2011;76(16):1389–1394. doi:10.1212/WNL.0b013e318216eb7b. [PubMed](#)
12. Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. *PLoS One*. 2013;8(9):e74916. doi:10.1371/journal.pone.0074916. [PubMed](#)
13. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. *JAMA*. 2008;300(19):2253–2262. doi:10.1001/jama.2008.683. [PubMed](#)
14. Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. *Alzheimers Res Ther*. 2012;4:43. doi:10.1186/alzrt146. [DOI](#)
15. Basheer A, Agarwal A, Mishra B, et al. Use of Bacopa monnieri in the treatment of dementia due to Alzheimer disease: systematic review of randomized controlled trials. *Interact J Med Res*. 2022;11(2):e38542. doi:10.2196/38542. [PubMed](#)
16. Snow AD, Castillo GM, Nguyen BP, et al. The Amazon rain forest plant *Uncaria tomentosa* (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. *Sci Rep*. 2019;9:561. doi:10.1038/s41598-019-38645-0. [PubMed](#)
17. National Center for Complementary and Integrative Health. Cat's claw. U.S. National Institutes of Health. [NCCIH fact sheet](#)
18. Shrestha HL, Shrestha L, McArthur M, et al. Traditional healing and medicine in dementia care for Indigenous populations in North America, Australia, and New Zealand: exploring culturally-safe dementia care policy from a global perspective. *Alzheimers Dement (Amst)*. 2024;16(4):e12620. doi:10.1002/dad2.12620. [PubMed](#)
19. Carroll SR, Garba I, Figueroa-Rodríguez OL, et al. The CARE Principles for Indigenous Data Governance. *Data Sci J*. 2020;19:43. doi:10.5334/dsj-2020-043. [DOI](#)
20. Howard R, Gathercole R, Bradley R, et al. The effectiveness and cost-effectiveness of assistive technology and telecare for independent living in dementia: a randomised controlled trial. *Age Ageing*. 2021;50(3):882–890. doi:10.1093/ageing/afaa284. [PubMed](#)
21. Harris N, Boyd H, Evans N, et al. A preliminary evaluation of a client-centred prompting tool for supporting everyday activities in individuals with mild to moderate levels of cognitive impairment due to dementia. *Dementia (London)*. 2021;20(3):867–883. doi:10.1177/1471301220911322. [PubMed](#)
22. Cannings M, Brookman R, Parker S, et al. Optimizing technology-based prompts for supporting people living with dementia in completing activities of daily living at home: experimental approach to prompt modality, task breakdown, and attentional support. *JMIR Aging*. 2024;7:e56055. doi:10.2196/56055. [PubMed](#)
23. World Health Organization. Risk reduction of cognitive decline and dementia: WHO guideline, second edition. Geneva: WHO; 2026. [WHO guideline](#)
24. Gathercole R, Bradley R, Harper E, et al. Assistive technology and telecare to maintain independent living at home for people with dementia: the ATTILA RCT. *Health Technol Assess*. 2021;25(19):1–156. doi:10.3310/hta25190. [PubMed](#)